Dosing and Administration Strategies of Tocilizumab in Patients With COVID-19: A Retrospective Cohort Analysis
Annals of Pharmacotherapy · 2024
DOI: 10.1177/10600280231190401 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Annals of Pharmacotherapy, 2024. Verfasst von Taylor D Steuber und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University of Missouri-Kansas City, Columbia, MO, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, COVID-19, COVID-19 Drug Treatment. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
Background
Tocilizumab may reduce the risk of death, length of stay, and time of mechanical ventilation in patients hospitalized with COVID-19. Limited data are available evaluating low-dose subcutaneous administration of tocilizumab in this setting.
Objective
To compare outcomes of 2 tocilizumab dosing and administration strategies in patients hospitalized with COVID-19.
Methods
A retrospective, observational cohort study was conducted to compare clinical outcomes in patients hospitalized with COVID-19 receiving tocilizumab 400 mg intravenously (400 mg IV) or 162 mg subcutaneously (162 mg SC). Hospitalized patients receiving a single dose of tocilizumab were eligible for inclusion and grouped by dosing and administration strategy. The primary endpoint was ventilator-free days at day 28. Secondary endpoints included length of stay (LOS), intensive care unit (ICU) LOS, mechanical ventilation required after dose, 28-day readmission, 28-day mortality, and change in inflammatory markers.
Results
A total of 303 patients were included, with 147 who received tocilizumab 400 mg IV and 156 who received 162 mg SC. There was no significant difference in average ventilator-free days at day 28 in patients receiving 400 mg IV compared with 162 mg SC (26.4 ± 5.3 vs 25.6 ± 6.8 days, respectively; P = 0.812). There was also no difference in LOS (10.4 ± 12.6 vs 10.5 ± 14.0 days; P = 0.637), ICU LOS (3.9 ± 9.0 vs 3.5 ± 8.3 days; P = 0.679), mechanical ventilation after dose (15.6% vs 19.2%; P = 0.412), 28-day readmission (6.1% vs 9.6%; P = 0.268), or 28-day mortality (23.1% vs 25.6%; P = 0.611). Finally, there was no difference regarding change in inflammatory markers at 48 hours ( P > 0.05 for all interactions). Conclusion and Relevance: In this retrospective study involving hospitalized patients with COVID-19, there was no difference between tocilizumab 162 mg SC and 400 mg IV in terms of efficacy. The 162 mg SC dose may be a reasonable alternative to traditional doses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, University of Missouri-Kansas City, Columbia, MO, USA.
- Harrison College of Pharmacy, Auburn University, Auburn, AL, USA.
- Department of Pharmacy, Huntsville Hospital, Huntsville, AL, USA.
- Department of Internal Medicine, Huntsville Hospital, Huntsville, AL, USA.
- Alabama Infectious Disease Center, Huntsville, AL, USA.
ORCID-Profile: Taylor D Steuber
Zitieren
APA
Steuber, T. D., Rosandich, T., Cadwallader, T., Steil, L., Belk, M., Yendrapalli, U., Hassoun, A., & Edwards, J. (2024). Dosing and Administration Strategies of Tocilizumab in Patients With COVID-19: A Retrospective Cohort Analysis. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280231190401
Vancouver
Steuber TD, Rosandich T, Cadwallader T, Steil L, Belk M, Yendrapalli U, et al. Dosing and Administration Strategies of Tocilizumab in Patients With COVID-19: A Retrospective Cohort Analysis. Annals of Pharmacotherapy. 2024. doi:10.1177/10600280231190401
BibTeX
@article{Steuber2024,
author = {Steuber, Taylor D and Rosandich, Thomas and Cadwallader, Tiffany and Steil, Lauren and Belk, Madeline and Yendrapalli, Usha and Hassoun, Ali and Edwards, Jonathan},
title = {Dosing and Administration Strategies of Tocilizumab in Patients With COVID-19: A Retrospective Cohort Analysis},
journal = {Annals of Pharmacotherapy},
year = {2024},
doi = {10.1177/10600280231190401}
}
EUVIMED